Our site in Hungary
In Hungary, we manufacture vaccines in Gödöllő in Pest County, 30km northeast of Budapest.
Contact details
GlaxoSmithKline Biologicals Kft.
Homoki Nagy István utca 1. Gödöllő
2100
Tel: +36 28 529 960
Our manufacturing site produces critical components for GSK’s vaccines against Diphtheria and Tetanus and pneumococcal disease. These components are distributed to GSK sites globally and contribute to the manufacture of around 100 million doses of GSK vaccine to prevent disease in children and adults, making GSK Gödöllő, a vital part of the GSK manufacturing network.
There has been a scientific presence at Gödöllő for over 50 years and the vaccine site was acquired by GSK over 20 years ago and remains a global centre of excellence for vaccine manufacturing with a focus on sustainability, the use of state of the art technologies and the development of a thriving workforce.
Careers
GSK has a proud history in Hungary and we continue to seek talented individuals looking to build their career in the GSK manufacturing network . If you are interested in joining our team, see current job vacancies. Read what our employees say about us.
Read about our global company purpose, strategy and culture at Company | GSK.
Tel: +36 80 088 309
Email: hun.medinfo@gsk.com
Online: Patient safety reporting form (Preferred method of contact)
Tel: +36 80 088 309
Email: hungary.ph_safety@gsk.com
Please contact Berlin-Chemie Menarini
Tel: +36 1 799 7320
Please contact Phoenix Group
Tel: +36 27 889 277
EFPIA disclosure
GSK fully supports the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfer of value from pharmaceutical companies to healthcare professionals and healthcare organisations
We believe that it helps to create a better understanding about how the pharmaceutical industry partners and collaborates with HCPs and HCOs, and so increase confidence in the way that industry and the healthcare professions work together.
We publish disclosure reports in line with the EFPIA Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.
